Medical Technology Leadership Forum, USA.
J Law Med Ethics. 2009 Winter;37(4):629-32. doi: 10.1111/j.1748-720X.2009.00436.x.
This article seeks to provide insights into appropriate FDA oversight of nanotechnology. This commentary identifies limitations in the methodology employed and concludes that the analysis would be stronger with a more in-depth institutional dimension based on administrative law and political science research.
本文旨在探讨美国食品和药物管理局（FDA）对纳米技术进行适当监管的问题。本评论指出了所采用方法的局限性，并得出结论，若能基于行政法和政治科学研究，更深入地从制度层面进行分析，结论将会更为有力。
